A Phase 1 Open-label Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Relapsed/refractory Acute Myeloid Leukemia (aml)
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patient has a confirmed diagnosis Relapsed/Refractory Acute Myeloid Leukemia (AML). 2) Patient has received, and has progressed, recurred, or is intolerant of approved therapeutic options that are available, or declines treatment with these therapies. 3) Eastern Cooperative Oncology Group (ECOG) performance status is 0 to 2.

You may not be eligible for this study if the following are true:

  • 1) Diagnosis of acute promyelocytic leukemia (APL). 2) Active central nervous system (CNS) leukemia. 3) Isolated extramedullary relapse.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.